Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of medicinal composition containing ashwagandha and application thereof

A kind of technology of ashwagandha, composition

Active Publication Date: 2020-06-16
PEKING UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] When people in the field of medicine use withafabain A and quercetin, they will inevitably inhibit cell activity, and this problem cannot be solved. In addition, because it has certain toxicity and has a slight central nervous system inhibitory effect, so the use of withan As a drug to treat neurodegenerative diseases, there are still some obstacles to play a neuroprotective role

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of medicinal composition containing ashwagandha and application thereof
  • A kind of medicinal composition containing ashwagandha and application thereof
  • A kind of medicinal composition containing ashwagandha and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] To treat Parkinson's disease:

[0041] (Related Behavioral Indicators)

[0042] Establishment of MPTP-induced Parkinson's disease model: After the mice were adaptively fed for 1 week, C57BL / 6 mice weighing more than 22 g were randomly selected, and 30 mg / kg MPTP solution was injected intraperitoneally, once a day, for 5 consecutive days.

[0043] At this time, the MPTP injection group (hereinafter referred to as the model group) was randomly divided into 4 groups, namely the model + control solvent group, the model + withaferin A group, the model + quercetin group, and the model + withaferin A + quercetin group. Group. Among them, each group of mice was injected intraperitoneally with withaferin A (20 μg / kg), quercetin (30 mg / kg), and the combination of withaferin A+quercetin (withaferin A 10 μg / kg, quercetin 15 mg / kg). kg), and an equal volume of control solvent.

[0044] After 7 days of intraperitoneal injection of each group of drugs and control solvent, the chang...

Embodiment 2

[0079] A mouse model of Parkinson's disease induced by MPTP was established (the method is the same as in Example 1). The MPTP injection group (hereinafter referred to as the model group) was randomly divided into 4 groups, namely the model + control solvent group, the model + withaferin A group, the model + quercetin group, and the model + withaferin A + quercetin group. Among them, each group of mice was injected intraperitoneally with withaferin A (20 μg / kg), quercetin (3 mg / kg), and the combination of withaferin A+quercetin (withaferin A 10 μg / kg, quercetin 1.5 mg / kg), and an equal volume of control solvent.

[0080] After 7 days of intraperitoneal injection of each group of drugs and control solvent, the changes of behavioral indexes in each group were detected. The method of balance beam experiment is the same as embodiment 1, and the results are shown in Table 5.

[0081] Table 5 Balance Beam Experimental Results

[0082]

[0083] The rod climbing test method is ...

Embodiment 3

[0094] Protective effect on dopaminergic neurons in substantia nigra and striatum:

[0095] Tyrosine hydroxylase (TH) is the rate-limiting enzyme of dopamine synthesis in the brain, and its level represents the ability of mice to synthesize dopamine. Therefore, tyrosine hydroxylase is often used as an indicator of dopamine secretion ability in mice.

[0096] After the establishment of the MPTP model, the establishment of the MPTP model and the dosage of the drug were the same as in Example 1. After 7 days of intraperitoneal injection of the drug and the control solvent in each group, the levels of tyrosine hydroxylase in the substantia nigra pars compacta of mice in each group were detected using immunohistochemical technology , the results are shown in Table 9.

[0097] The results were: compared with the normal group, the number of TH positive neurons in the substantia nigra pars compacta of the mice in the model group decreased significantly, that is, obvious dopaminergic n...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a medicinal composition containing withaferin A and an application thereof, which belong to the technical fields of medical science and biology. The medicinal composition comprises withaferin A and quercetin, the mass ratio of the withaferin A to quercetin is 1: (1 to 1500). In the present invention, the medicinal composition is possible to prevent and treat neurodegenerative diseases, protects neurons, improves the distribution and morphology of tyrosine hydroxylase-positive neurons in the mass ratio of withaferin A to quercetin, treats neuroinflammation, not only significantly reduces the usage dosage, but also achieves better results than single usage.

Description

technical field [0001] The invention belongs to the technical fields of medicine and biology, and in particular relates to a pharmaceutical composition containing withaferin A and its application. Background technique [0002] Neurodegenerative diseases are a group of diseases caused by the gradual loss of the structure or function of neurons in the body, including Parkinson's disease, Alzheimer's disease, Huntington's disease, etc.; the etiology of such diseases is not yet clear, and there is no effective cure means, and seriously threaten the quality of life of patients. [0003] Alzheimer's disease (AD) is a central nervous system degenerative disease with insidious onset and age-related chronic progressive development. Clinically, it is characterized by comprehensive dementia such as memory impairment, aphasia, apraxia, agnosia, impairment of visuospatial skills, executive dysfunction, and personality and behavior changes. The etiology is still unknown. With the aging ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/352A61K31/585A61P25/16A61P25/28A61P25/00A61P29/00
CPCA61K31/352A61K31/585A61P25/00A61P25/16A61P25/28A61P29/00A61K2300/00
Inventor 郑瑞茂赵淼
Owner PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com